Bone and soft tissue sarcomas, tumors of the skinBone and soft tissue sarcomas, tumors of the skinСаркомы костей, мягких тканей и опухоли кожи2219-46142782-3687Publishing House ABV Press359BONE SARCOMASСАРКОМЫ КОСТЕЙTreatment results of pathological fractures of the long bones in patients with breast cancerРезультаты хирургического лечения патологических переломов длинных трубчатых костей у пациенток, страдающих раком молочной железыRadchenkoA. I.РадченкоА. И.
Belarus

Minsk

г. Минск

aradchenko@mail.ruZhukovecA. G.ЖуковецА. Г.
Belarus

Minsk

г. Минск

BogdaevJu. M.БогдаевЮ. М.
Belarus

Minsk

г. Минск

N.N. Alexandrov National Cancer Center of BelarusРеспубликанский научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова221020168311152201202222012022Copyright ©; 2016, Radchenko A.I., Zhukovec A.G., Bogdaev J.M.Copyright ©; 2016, Радченко А.И., Жуковец А.Г., Богдаев Ю.М.2016Radchenko A.I., Zhukovec A.G., Bogdaev J.M.Радченко А.И., Жуковец А.Г., Богдаев Ю.М.https://creativecommons.org/licenses/by/4.0https://sarbon.abvpress.ru/jour/article/view/359

Background. To analyze results of surgical treatment of pathological fractures in patients with long bones metastasis from breast cancer.Methods. 22 patients with pathological fractures of the long bones were analyzed retrospectively. methods of bone reconstruction were intramedullary and plate osteosynthesis (53,8%), arthroplasty (46,2%).Results. The overall survival was 66,2% at 1 year and 36,0% at 3 years (the mean survival time was 16,6 months). Visceral metastases have exerted statistically significant negative impact on survival (p=0,011). The complication rate after surgery was 27,3%. Quality of life and extremity function were significantly improved after surgical treatment (p=0,005).Conclusions. active surgical treatment of long bone pathological fractures in patients with breast cancer allows to improve quality of life, get good functional results and make conditions for special treatment.

Цель работы. проанализировать результаты хирургического лечения патологических переломов длинных трубчатых костей у пациенток, страдающих раком молочной железы.Методы. В ретроспективное исследование были включены 22 пациентки, которым было проведено хирургическое лечение по поводу патологических переломов длинных трубчатых костей. использовались интрамедуллярный и накостный остеосинтез (53,8%), эндопротезирование (46,2%).Результаты. общая 1- и 3-летняя выживаемость составила 66,2 и 36% соответственно (медиана выживаемости – 16,6 мес). Висцеральные метастазы статистически значимо негативно влияют на выживаемость (р=0,011). Частота послеоперационных осложнений составила 27,3%. хирургическое лечение позволило статистически значимо улучшить функцию конечности и качество жизни пациенток (р=0,005).Выводы. активное хирургическое лечение пациенток с патологическими переломами длинных трубчатых костей, обусловленных метастазами рака молочной железы, позволяет улучшить качество жизни, получить удовлетворительный функциональный результат и создать условия для проведения специального лечения.

breast cancerpathological fracturelong bonessurgical treatmentрак молочной железыпатологический переломдлинные трубчатые костихирургическое лечение1. Океанов А.Е., Моисеев П.И., Левин Л.Ф. Статистика онкологических заболеваний. Минск: РНПЦ ОМР. 2013, 124 с.Океанов А.Е., Моисеев П.И., Левин Л.Ф. Статистика онкологических заболеваний. Минск: РНПЦ ОМР. 2013, 124 с.2. Sogaard K.K., Cronin Fenton D.P., Pedersen L. et al. Survival in Danish patients with breast cancer and inflammatory bowel disease: a nationwide cohort study. Inflamm. Bowel. Dis. 2008, v. 14, p. 519-525.Sogaard K.K., Cronin Fenton D.P., Pedersen L. et al. Survival in Danish patients with breast cancer and inflammatory bowel disease: a nationwide cohort study. Inflamm. Bowel. Dis. 2008, v. 14, p. 519-525.3. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 2006, v. 12, p. 6243-6249.Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 2006, v. 12, p. 6243-6249.4. Jensen A.O., Jacobsen J.B., Norgaard M. et al. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer. 2011, v. 11, p. 329-338.Jensen A.O., Jacobsen J.B., Norgaard M. et al. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer. 2011, v. 11, p. 329-338.5. Saad F., Lipton A., Cook R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007, v. 110 (8), p. 1860-1867.Saad F., Lipton A., Cook R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007, v. 110 (8), p. 1860-1867.6. Lipton A., Theriault R.L., Hortobagyi G.N. et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer. 2000, v. 88, p. 1082-1090.Lipton A., Theriault R.L., Hortobagyi G.N. et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer. 2000, v. 88, p. 1082-1090.7. Hortobagyi G.N., Theriault R.L., Lipton A. et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate, Protocol 19, Aredia Breast Cancer Study Group. J. Clin. Oncol. 1998, v. 16, p. 2038-2044.Hortobagyi G.N., Theriault R.L., Lipton A. et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate, Protocol 19, Aredia Breast Cancer Study Group. J. Clin. Oncol. 1998, v. 16, p. 2038-2044.8. Hortobagyi G.N., Theriault R.L., Porter L. et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med. 1996, v. 335, p. 1785-1791.Hortobagyi G.N., Theriault R.L., Porter L. et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med. 1996, v. 335, p. 1785-1791.9. Hird et al. Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three canadian cancer centers. Int. J. Radiat. Oncol. Biol. Phys. 2009, v. 75, p. 193-197.Hird et al. Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three canadian cancer centers. Int. J. Radiat. Oncol. Biol. Phys. 2009, v. 75, p. 193-197.10. Hamouda et al. Single versus conventional fractionated radiotherapy in the palliation of painful bone metastases. Gulf. J. Oncolog. 2007, v. 1, p. 35-41.Hamouda et al. Single versus conventional fractionated radiotherapy in the palliation of painful bone metastases. Gulf. J. Oncolog. 2007, v. 1, p. 35-41.11. Hartsell et al. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J. Nat. Cancer Inst. 2005, v. 97, p. 798-804.Hartsell et al. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J. Nat. Cancer Inst. 2005, v. 97, p. 798-804.12. Liepe et al. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl. Med. Commun. 2007, v. 28, p. 623-630.Liepe et al. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl. Med. Commun. 2007, v. 28, p. 623-630.13. Liepe et al. Systemic radionuclide therapy in pain palliation. Am. J. Hosp. Palliat. Care. 2005, v. 22, p. 457-464.Liepe et al. Systemic radionuclide therapy in pain palliation. Am. J. Hosp. Palliat. Care. 2005, v. 22, p. 457-464.14. Wedin R., Bauer H.C., Rutqvist L.E. Surgical treatment for skeletal breast cancer metastases: a population-based study of 641 patients. Cancer. 2001, v. 92 (2), p. 257-262.Wedin R., Bauer H.C., Rutqvist L.E. Surgical treatment for skeletal breast cancer metastases: a population-based study of 641 patients. Cancer. 2001, v. 92 (2), p. 257-262.15. Choi B.S., Robins H.I. Primary disease resection in metastatic breast cancer improves survival. J. Clin. Oncol. 2007, v. 25 (5), p. 603-604.Choi B.S., Robins H.I. Primary disease resection in metastatic breast cancer improves survival. J. Clin. Oncol. 2007, v. 25 (5), p. 603-604.16. Jubelirer S.J., Wilson R., Summers L., Richardson S. Prognostic factors determining survival in breast cancer patients presenting with metastatic disease. W. V. Med. J. 1990, v. 86 (1), p. 7-9.Jubelirer S.J., Wilson R., Summers L., Richardson S. Prognostic factors determining survival in breast cancer patients presenting with metastatic disease. W. V. Med. J. 1990, v. 86 (1), p. 7-9.17. Bauer H.C., Wedin R. Survival after surgery for spinal and extremity metastases. Prognosticationin 241 patients. Acta Orthop. Scand. 1995, v. 66, p. 143-146.Bauer H.C., Wedin R. Survival after surgery for spinal and extremity metastases. Prognosticationin 241 patients. Acta Orthop. Scand. 1995, v. 66, p. 143-146.18. Тепляков В.В., Амирасланов А.Т., Карпенко В.Ю. с соавт. Современные подходы к хирургическому лечению метастазов злокачественных опухолей в кости. Вопросы онкологии. 2005, № 3, с. 377-381.Тепляков В.В., Амирасланов А.Т., Карпенко В.Ю. с соавт. Современные подходы к хирургическому лечению метастазов злокачественных опухолей в кости. Вопросы онкологии. 2005, № 3, с. 377-381.19. Sukirtha T. et al. Quality of life measurement in bone metastases: a literature review. Journal of pain research. 2008, v. 1, p. 49-58.Sukirtha T. et al. Quality of life measurement in bone metastases: a literature review. Journal of pain research. 2008, v. 1, p. 49-58.